Therapeutic potential of vasopressin-receptor antagonists in heart failure

Journal of Pharmacological Sciences

Volumn 124, Issue 1, 2014, Pages 1-6

  Izumi, Yasukatsu ^a   Miura, Katsuyuki ^a   Iwao, Hiroshi ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Arginine vasopressin; Diuretic; Heart failure; Vasopressin receptor antagonist

Indexed keywords

CONIVAPTAN; ELECTROLYTE; LIXIVAPTAN; MOZAVAPTAN; NELIVAPTAN; RELCOVAPTAN; SATAVAPTAN; TOLVAPTAN; UNCLASSIFIED DRUG; VASOPRESSIN 2 RECEPTOR ANTAGONIST; VASOPRESSIN RECEPTOR ANTAGONIST; VASOPRESSIN V1A RECEPTOR; VASOPRESSIN V1B RECEPTOR; VASOPRESSIN V2 RECEPTOR;

DIURESIS; DRUG EFFECT; DRUG SELECTIVITY; DYSMENORRHEA; ELECTROLYTE TRANSPORT; HEART FAILURE; HUMAN; HYPERVOLEMIC HYPONATREMIA; HYPONATREMIA; HYPOTONIC DIURESIS; MENTAL DISEASE; NONHUMAN; RAYNAUD PHENOMENON; REVIEW; TOCOLYSIS;

ANIMALS; ARGININE VASOPRESSIN; BENZAMIDES; BENZAZEPINES; BODY WATER; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; HEART FAILURE; HOMEOSTASIS; HUMANS; HYPONATREMIA; MORPHOLINES; PYRROLES; RECEPTORS, VASOPRESSIN; SPIRO COMPOUNDS; VENTRICULAR REMODELING;

EID: 84892684025     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.13R13CP     Document Type: Review

References (30)

1. Fang J, Mensah GA, Croft J.B., Keenan NL Heart failure-related hospitalization in the U.S., 1979 to 2004. J Am Coll Cardiol. 2008;52:428-434.
2. Rosamond W, Flegal K, Furie K., Go A, Greenlund K, Haase N., et al Heart disease and stroke statistics-2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2008;117:e25-e146.
3. Croft JB, Giles WH, Pollard R.A., Keenan NL, Casper ML, Anda RF Heart failure survival among older adults in the United States: a poor prognosis for an emerging epidemic in the Medicare population. Arch Intern Med. 1999;159:505-510.
4. Hunt SA, American College of C, American Heart Association Task Force on Practice G. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol. 2005;46: e1-e82.
5. Lee CR, Watkins ML, Patterson J.H., Gattis W., O'Connor CM, Gheorghiade M, et al Vasopressin: a new target for the treatment of heart failure. Am Heart J. 2003;146:9-18.
6. Carmichael MC, Kumar R. Molecular biology of vasopressin receptors. Semin Nephrol. 1994;14:341-348.
7. Birnbaumer M. Vasopressin receptors. Trends Endocrinol Metab. 2000;11:406-410.
8. Nielsen S, Kwon TH, Christensen B.M., Promeneur D., Frokiaer J, Marples D. Physiology and pathophysiology of renal aquaporins. J Am Soc Nephrol. 1999;10:647-663.
9. Francis GS, Benedict C, Johnstone D.E., Kirlin PC, Nicklas J, Liang CS, et al Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation. 1990; 82:1724-1729.
10. Goldsmith SR, Francis GS, Cowley AW Jr, Levine TB, Cohn JN Increased plasma arginine vasopressin levels in patients with congestive heart failure. J Am Coll Cardiol. 1983;1:1385-1390.
11. Schrier RW, Martin PY Recent advances in the understanding of water metabolism in heart failure. Adv Exp Med Biol. 1998;449:415-426.
12. Chin MH, Goldman L. Correlates of major complications or death in patients admitted to the hospital with congestive heart failure. Arch Intern Med. 1996;156:1814-1820.
13. Goldsmith SR, Francis GS, Cowley AW Jr, Goldenberg IF, Cohn JN Hemodynamic effects of infused arginine vasopressin in congestive heart failure. J Am Coll Cardiol. 1986;8:779-783.
14. Nakamura Y, Haneda T, Osaki J., Miyata S, Kikuchi K. Hypertrophic growth of cultured neonatal rat heart cells mediated by vasopressin V(1A) receptor. Eur J Pharmacol. 2000;391: 39-48.
15. Costello-Boerrigter L.C., Smith WB, Boerrigter G, Ouyang J., Zimmer CA, Orlandi C, et al Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure. Am J Physiol Renal Physiol. 2006;290:F273-F278.
16. Rehsia NS, Dhalla NS Potential of endothelin-1 and vasopressin antagonists for the treatment of congestive heart failure. Heart Fail Rev. 2010;15:85-101.
17. Valania G, Singh M, Slawsky MT Targeting hyponatremia and hemodynamics in acute decompensated heart failure: is there a role for vasopressin antagonists? Curr Heart Fail Rep. 2011;8:198-205.
18. Gheorghiade M, Gattis WA, O'Connor CM, Adams KF Jr, Elkayam U, Barbagelata A, et al Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA. 2004;291:1963-1971.
19. Gheorghiade M, Konstam MA, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, et al Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA. 2007;297:1332-1343.
20. Udelson JE, Orlandi C, Ouyang J., Krasa H, Zimmer CA, Frivold G, et al Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: an international, multicenter, randomized, placebo-controlled trial. J Am Coll Cardiol. 2008;52: 1540-1545.
21. Udelson JE, Bilsker M, Hauptman P.J., Sequeira R., Thomas I, O'Brien T, et al A multicenter, randomized, double-blind, placebo-controlled study of tolvaptan monotherapy compared to furosemide and the combination of tolvaptan and furosemide in patients with heart failure and systolic dysfunction. J Card Fail. 2011;17:973-981.
22. Abraham WT, Shamshirsaz AA, McFann K, Oren R.M., Schrier RW Aquaretic effect of lixivaptan, an oral, non-peptide, selective V2 receptor vasopressin antagonist, in New York Heart Association functional class II and III chronic heart failure patients. J Am Coll Cardiol. 2006;47:1615-1621.
23. Goldsmith SR, Elkayam U, Haught W.H., Barve A., He W. Efficacy and safety of the vasopressin V1A/V2-receptor antagonist conivaptan in acute decompensated heart failure: a dose-ranging pilot study. J Card Fail. 2008;14:641-647.
24. Naitoh M, Suzuki H, Murakami M., Matsumoto A, Arakawa K, Ichihara A., et al Effects of oral AV P receptor antagonists OPC-21268 and OPC-31260 on congestive heart failure in conscious dogs. Am J Physiol. 1994;267:H2245-H2254.
25. Onogawa T, Sakamoto Y, Nakamura S., Nakayama S, Fujiki H, Yamamura Y. Effects of tolvaptan on systemic and renal hemodynamic function in dogs with congestive heart failure. Cardiovasc Drugs Ther. 2011;25 Suppl 1:S67-S76.
26. Veeraveedu PT, Watanabe K, Ma M., Palaniyandi SS, Yamaguchi K, Kodama M, et al Effects of V2-receptor antagonist tolvaptan and the loop diuretic furosemide in rats with heart failure. Biochem Pharmacol. 2008;75:1322-1330.
27. Morooka H, Iwanaga Y, Tamaki Y., Takase T, Akahoshi Y, Nakano Y., et al Chronic administration of oral vasopressin type 2 receptor antagonist tolvaptan exerts both myocardial and renal protective effects in rats with hypertensive heart failure. Circ Heart Fail. 2012;5:484-492.
28. Kuwahara K, Nishikimi T, Nakao K. Transcriptional regulation of the fetal cardiac gene program. J Pharmacol Sci. 2012;119: 198-203.
29. Yamazaki T, Izumi Y, Nakamura Y., Yamashita N, Fujiki H, Osada-Oka M, et al Tolvaptan improves left ventricular dysfunction after myocardial infarction in rats. Circ Heart Fail. 2012;5:794-802.
30. Yamazaki T, Nakamura Y, Shiota M., Osada-Oka M, Fujiki H, Hanatani A., et al Tolvaptan attenuates left ventricular fibrosis after acute myocardial infarction in rats. J Pharmacol Sci. 2013;123:58-66.